Table 3.

Results of IMvigor 210; Phase II study of atezolizumab as a single agent in locally advance or metastatic bladder cancer patients.

	Number of patients (N −100%)	Any Grade TrAEs(%)	Grade ≥3 TrAEs(%)	OS, months	Median PFS, months	ORR(%)
Treatment naïve and cisplatin ineligible24	119	66	16	15.9	2.7	23
Progressed on or following platinum-based chemotherapy25	310	69	16	7.9	2.1	45

ORR –Overall response rate; PFS- Progression free survival; OS- Overall survival; TrAES- Treatment related adverse events.